EP. 1: The Evolving Treatment Landscape of Leukemia
James K. McCloskey, MD, a specialist in leukemia, discusses how the treatment landscape has changed in recent years.
EP. 2: Recent Data from ASH 2023 in Leukemia
Following ASH 2023, a hematologist-oncologist discusses recent updates on approved and emerging therapies for patients with leukemia, highlighting the TRANSFORM-1 trial looking at navitoclax plus ruxolitinib.
EP. 3: Long-Term Results of the OPTIC Trial in CML
Focusing on chronic myeloid leukemia, James K. McCloskey, MD, reviews the long-term results of the OPTIC trial presented at ASH 2023.
EP. 4: Subgroup Analysis of the Phase 3 PhALLCON Study of Ponatinib in Ph+ ALL
An expert on leukemia provides comprehensive insights on the subgroup analysis of the phase 3 PhALLCON study of ponatinib in Ph+ acute lymphoblastic leukemia.
EP. 5: Key Takeaways from Recent Updates in Leukemia
James K. McCloskey, MD, provides an overview of key takeaways from recent studies presented at the 2023 ASH Annual Meeting in leukemia.
EP. 6: Challenges in Managing Adverse Events and Unmet Needs in Leukemia
Dr McCloskey highlights challenges in adverse event management and discusses unmet needs in the treatment of patients with leukemia.
EP. 7: The Evolving Lymphoma Treatment Landscape
Lori A. Leslie, MD, a specialist in lymphoma, provides an overview of recent changes in the overall treatment landscape.
EP. 8: Subcutaneous Mosunetuzumab in Follicular Lymphoma
A hematologist-oncologist discusses a recent abstract looking at subcutaneous mosunetuzumab in the first line for patients with follicular lymphoma.
EP. 9: Recent Data on Axi-Cel in Lymphoma
Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.
EP. 10: Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma
Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.
EP. 11: CAR T-Cell Therapy: Managing Adverse Events and Assessing Patient Response in Lymphoma
Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra.
EP. 12: Unmet Needs and Challenges in Lymphoma
Looking to the future, Lori A. Leslie, MD, offers closing thoughts on unmet needs and potential improvements in the lymphoma treatment space.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
